Potential of miRNAs in Plasma Extracellular Vesicle for the Stratification of Prostate Cancer in a South African Population
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patient Cohort
2.2. Extracellular Vesicle Isolation and Characterization
2.3. TEM Image Analysis
2.4. Small RNA Sequencing in Plasma EVs
2.5. TCGA Prostatic Tissue miRNA
2.6. MicroRNA Enrichment
2.7. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR)
2.8. Statistical Analysis
3. Results
3.1. Sequencing of EV miRNA from Prostate Cancer Samples
3.2. Identification of EV miRNA Target Genes
3.3. Validation of miRNA Expression by RT-qPCR Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Powell, I.J. The precise role of ethnicity and family history on aggressive prostate cancer: A review analysis. Arch. Esp. Urol. 2011, 64, 711–719. [Google Scholar] [PubMed]
- Jaratlerdsiri, W.; Jiang, J.; Gong, T.; Patrick, S.M.; Willet, C.; Chew, T.; Lyons, R.J.; Haynes, A.-M.; Pasqualim, G.; Louw, M.; et al. African-specific molecular taxonomy of prostate cancer. Nature 2022, 609, 552–559. [Google Scholar] [CrossRef] [PubMed]
- Adeola, H.A.; Blackburn, J.M.; Rebbeck, T.R.; Zerbini, L.F. Emerging proteomics biomarkers and prostate cancer burden in Africa. Oncotarget 2017, 8, 37991–38007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adeola, H.A.; Smith, M.; Kaestner, L.; Blackburn, J.M.; Zerbini, L.F. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort. Oncotarget 2016, 7, 13945–13964. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cacciatore, S.; Wium, M.; Licari, C.; Ajayi-Smith, A.; Masieri, L.; Anderson, C.; Salukazana, A.S.; Kaestner, L.; Carini, M.; Carbone, G.M.; et al. Inflammatory metabolic profile of South African patients with prostate cancer. Cancer Metab. 2021, 9, 29. [Google Scholar] [CrossRef]
- Hayes, J.H.; Barry, M.J. Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. JAMA 2014, 311, 1143–1149. [Google Scholar] [CrossRef]
- Schaeffer, E.; Srinivas, S.; Antonarakis, E.S.; Armstrong, A.J.; Bekelman, J.E.; Cheng, H.; D’Amico, A.V.; Davis, B.J.; Desai, N.; Dorff, T.; et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J. Natl. Compr. Cancer Netw. 2021, 19, 134–143. [Google Scholar] [CrossRef]
- Underwood, D.J.; Zhang, J.; Denton, B.T.; Shah, N.D.; Inman, B.A. Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag. Sci. 2012, 15, 293–309. [Google Scholar] [CrossRef] [Green Version]
- Schröder, F.H.; Hugosson, J.; Roobol, M.J.; Tammela, T.L.J.J.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N. Engl. J. Med. 2009, 360, 1320–1328. [Google Scholar] [CrossRef] [Green Version]
- Greene, K.L.; Albertsen, P.C.; Babaian, R.J.; Carter, H.B.; Gann, P.H.; Han, M.; Kuban, D.A.; Sartor, A.O.; Stanford, J.L.; Zietman, A.; et al. Prostate specific antigen best practice statement: 2009 update. J. Urol. 2013, 189, S2–S11. [Google Scholar] [CrossRef] [PubMed]
- Spugnini, E.P.; Logozzi, M.; Di Raimo, R.; Mizzoni, D.; Fais, S.; Di Raimo, R.; Mizzoni, D.; Fais, S. A role of tumor-released exosomes in paracrine dissemination and metastasis. Int. J. Mol. Sci. 2018, 19, 3968. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science 2020, 367, eaau6977. [Google Scholar] [CrossRef]
- Temilola, D.O.; Wium, M.; Coulidiati, T.H.; Adeola, H.A.; Carbone, G.M.; Catapano, C.V.; Zerbini, L.F. The Prospect and Challenges to the Flow of Liquid Biopsy in Africa. Cells 2019, 8, 862. [Google Scholar] [CrossRef] [Green Version]
- Camussi, G.; Deregibus, M.C.; Bruno, S.; Cantaluppi, V.; Biancone, L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010, 78, 838–848. [Google Scholar]
- Zaborowski, M.P.; Balaj, L.; Breakefield, X.O.; Lai, C.P. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience 2015, 65, 783–797. [Google Scholar] [CrossRef] [Green Version]
- Li, W.; Li, C.; Zhou, T.; Liu, X.; Liu, X.; Li, X.; Chen, D. Role of exosomal proteins in cancer diagnosis. Mol. Cancer 2017, 16, 145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 2018, 7, 1535750. [Google Scholar] [CrossRef] [Green Version]
- He, G.; Peng, X.; Wei, S.; Yang, S.; Li, X.; Huang, M.; Tang, S.; Jin, H.; Liu, J.; Zhang, S.; et al. Exosomes in the hypoxic TME: From release, uptake and biofunctions to clinical applications. Mol. Cancer 2022, 21, 19. [Google Scholar] [CrossRef]
- Sumrin, A.; Moazzam, S.; Khan, A.A.; Ramzan, I.; Batool, Z.; Kaleem, S.; Ali, M.; Bashir, H.; Bilal, M. Exosomes as biomarker of cancer. Brazilian Arch. Biol. Technol. 2018, 61, e18160730. [Google Scholar] [CrossRef]
- Lucci, A.; Hall, C.S.; Lodhi, A.K.; Bhattacharyya, A.; Anderson, A.E.; Xiao, L.; Bedrosian, I.; Kuerer, H.M.; Krishnamurthy, S. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol. 2012, 13, 688–695. [Google Scholar] [CrossRef]
- Nilsson, J.; Skog, J.; Nordstrand, A.; Baranov, V.; Mincheva-Nilsson, L.; Breakefield, X.O.; Widmark, A. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br. J. Cancer 2009, 100, 1603–1607. [Google Scholar] [CrossRef] [PubMed]
- Tavoosidana, G.; Ronquist, G.; Darmanis, S.; Yan, J.; Carlsson, L.; Wu, D.; Conze, T.; Ek, P.; Semjonow, A.; Eltze, E.; et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 8809–8814. [Google Scholar] [CrossRef]
- Overbye, A.; Skotland, T.; Koehler, C.J.; Thiede, B.; Seierstad, T.; Berge, V.; Sandvig, K.; Llorente, A. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget 2015, 6, 30357–30376. [Google Scholar] [CrossRef] [Green Version]
- Albino, D.; Falcione, M.; Uboldi, V.; Temilola, D.O.; Sandrini, G.; Merulla, J.; Civenni, G.; Kokanovic, A.; Stürchler, A.; Shinde, D.; et al. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. Commun. Biol. 2021, 4, 119. [Google Scholar] [CrossRef] [PubMed]
- Paccez, J.D.; Duncan, K.; Vava, A.; Correa, R.G.; Libermann, T.A.; Parker, M.I.; Zerbini, L.F. Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol. Biol. Cell 2015, 26, 821–831. [Google Scholar] [CrossRef]
- Paccez, J.D.; Vasques, G.J.; Correa, R.G.; Vasconcellos, J.F.; Duncan, K.; Gu, X.; Bhasin, M.; Libermann, T.A.; Zerbini, L.F. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 2013, 32, 689–698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Otsu, N. A threshold selection method from gray-level histograms. IEEE Trans. Syst. Man. Cybern. 1979, 9, 62–66. [Google Scholar] [CrossRef] [Green Version]
- Bushnell, B.; Rood, J.; Singer, E. BBMerge—Accurate paired shotgun read merging via overlap. PLoS ONE 2017, 12, e0185056. [Google Scholar] [CrossRef]
- Rahman, R.-U.; Gautam, A.; Bethune, J.; Sattar, A.; Fiosins, M.; Magruder, D.S.; Capece, V.; Shomroni, O.; Bonn, S. Oasis 2: Improved online analysis of small RNA-seq data. BMC Bioinform. 2018, 19, 54. [Google Scholar] [CrossRef] [Green Version]
- Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [Google Scholar] [CrossRef] [Green Version]
- Licursi, V.; Conte, F.; Fiscon, G.; Paci, P. MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinform. 2019, 20, 545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martens, M.; Ammar, A.; Riutta, A.; Waagmeester, A.; Slenter, D.N.; Hanspers, K.; Miller, R.A.; Digles, D.; Lopes, E.N.; Ehrhart, F.; et al. WikiPathways: Connecting communities. Nucleic Acids Res. 2021, 49, D613–D621. [Google Scholar] [CrossRef] [PubMed]
- Kern, F.; Fehlmann, T.; Solomon, J.; Schwed, L.; Grammes, N.; Backes, C.; van Keuren-Jensen, K.; Craig, D.W.; Meese, E.; Keller, A. miEAA 2.0: Integrating multi-species microRNA enrichment analysis and workflow management systems. Nucleic Acids Res. 2021, 48, W521–W528. [Google Scholar] [CrossRef]
- Meher, P.K.; Satpathy, S.; Rao, A.R. miRNALoc: Predicting miRNA subcellular localizations based on principal component scores of physico-chemical properties and pseudo compositions of di-nucleotides. Sci. Rep. 2020, 10, 14557. [Google Scholar] [CrossRef] [PubMed]
- De Rie, D.; Abugessaisa, I.; Alam, T.; Arner, E.; Arner, P.; Ashoor, H.; Åström, G.; Babina, M.; Bertin, N.; Burroughs, A.M.; et al. An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat. Biotechnol. 2017, 35, 872–878. [Google Scholar] [CrossRef]
- Chen, B.; Khodadoust, M.S.; Liu, C.L.; Newman, A.M.; Alizadeh, A.A. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol. Biol. 2018, 1711, 243–259. [Google Scholar] [CrossRef]
- Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. Immunity 2018, 48, 812–830.e14. [Google Scholar] [CrossRef] [Green Version]
- Cacciatore, S.; Tenori, L.; Luchinat, C.; Bennett, P.R.; MacIntyre, D.A. KODAMA: An R package for knowledge discovery and data mining. Bioinformatics 2017, 33, 621–623. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koliha, N.; Heider, U.; Ozimkowski, T.; Wiemann, M.; Bosio, A.; Wild, S. Melanoma Affects the Composition of Blood Cell-Derived Extracellular Vesicles. Front. Immunol. 2016, 7, 282. [Google Scholar] [CrossRef] [Green Version]
- Fernandes, R.C.; Toubia, J.; Townley, S.; Hanson, A.R.; Dredge, B.K.; Pillman, K.A.; Bert, A.G.; Winter, J.M.; Iggo, R.; Das, R.; et al. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Rep. 2021, 34, 108585. [Google Scholar] [CrossRef] [PubMed]
- Di Martino, M.T.; Arbitrio, M.; Caracciolo, D.; Cordua, A.; Cuomo, O.; Grillone, K.; Riillo, C.; Caridà, G.; Scionti, F.; Labanca, C.; et al. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Mol. Ther. Nucleic Acids 2022, 27, 1191–1224. [Google Scholar] [CrossRef]
- Zadra, G.; Photopoulos, C.; Loda, M. The fat side of prostate cancer. Biochim. Biophys. Acta 2013, 1831, 1518–1532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zadra, G.; Ribeiro, C.F.; Chetta, P.; Ho, Y.; Cacciatore, S.; Gao, X.; Syamala, S.; Bango, C.; Photopoulos, C.; Huang, Y.; et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 2019, 116, 631–640. [Google Scholar] [CrossRef] [Green Version]
- Labbé, D.P.; Zadra, G.; Yang, M.; Reyes, J.M.; Lin, C.Y.; Cacciatore, S.; Ebot, E.M.; Creech, A.L.; Giunchi, F.; Fiorentino, M.; et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat. Commun. 2019, 10, 4358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, L.; Zhang, L.; Montgomery, K.C.; Jiang, L.; Lyon, C.J.; Hu, T.Y. Advanced technologies for molecular diagnosis of cancer: State of pre-clinical tumor-derived exosome liquid biopsies. Mater. Today Bio 2023, 18, 100538. [Google Scholar] [CrossRef]
- Brase, J.C.; Johannes, M.; Schlomm, T.; Fälth, M.; Haese, A.; Steuber, T.; Beissbarth, T.; Kuner, R.; Sültmann, H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128, 608–616. [Google Scholar] [CrossRef]
- Fujita, K.; Nonomura, N. Role of Androgen Receptor in Prostate Cancer: A Review. World J. Mens. Health 2019, 37, 288–295. [Google Scholar] [CrossRef]
- Zhang, Z.; Karthaus, W.R.; Lee, Y.S.; Gao, V.R.; Wu, C.; Russo, J.W.; Liu, M.; Mota, J.M.; Abida, W.; Linton, E.; et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell 2020, 38, 279–296.e9. [Google Scholar] [CrossRef]
- Swinnen, J.V.; Esquenet, M.; Goossens, K.; Heyns, W.; Verhoeven, G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 1997, 57, 1086–1090. [Google Scholar]
- Das, R.; Gregory, P.A.; Fernandes, R.C.; Denis, I.; Wang, Q.; Townley, S.L.; Zhao, S.G.; Hanson, A.R.; Pickering, M.A.; Armstrong, H.K.; et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res. 2017, 77, 1021–1034. [Google Scholar] [CrossRef] [Green Version]
- Qi, K.; Chen, X.S.; Tian, T.; Xia, X.Y.; Xu, P. MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein. Oncol. Rep. 2017, 37, 803–812. [Google Scholar] [CrossRef]
- Gao, S.; Zhao, Z.; Wu, R.; Wu, L.; Tian, X.; Zhang, Z. MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer. Onco. Targets Ther. 2018, 11, 4837–4844. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selth, L.A.; Townley, S.L.; Bert, A.G.; Stricker, P.D.; Sutherland, P.D.; Horvath, L.G.; Goodall, G.J.; Butler, L.M.; Tilley, W.D. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br. J. Cancer 2013, 109, 641–650. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Petkevich, A.A.; Abramov, A.A.; Pospelov, V.I.; Malinina, N.A.; Kuhareva, E.I.; Mazurchik, N.V.; Tarasova, O.I. Exosomal and non-exosomal mirna expression levels in patients with hcv-related cirrhosis and liver cancer. Oncotarget 2021, 12, 1697–1706. [Google Scholar] [CrossRef]
- Lange, T.; Stracke, S.; Rettig, R.; Lendeckel, U.; Kuhn, J.; Schlüter, R.; Rippe, V.; Endlich, K.; Endlich, N. Identification of miR-16 as an endogenous reference gene for the normalization of urinary exosomal miRNA expression data from CKD patients. PLoS ONE 2017, 12, e0183435. [Google Scholar] [CrossRef]
- Solayman, M.H.M.; Langaee, T.; Patel, A.; El-Wakeel, L.; El-Hamamsy, M.; Badary, O.; Johnson, J.A. Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Mol. Biotechnol. 2016, 58, 179–187. [Google Scholar] [CrossRef] [Green Version]
- Benson, E.A.; Skaar, T.C. Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. Drug Metab. Dispos. 2013, 41, 1778–1781. [Google Scholar] [CrossRef] [Green Version]
- Kroh, E.M.; Parkin, R.K.; Mitchell, P.S.; Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50, 298–301. [Google Scholar] [CrossRef] [Green Version]
- Wong, T.-S.; Liu, X.-B.; Wong, B.Y.-H.; Ng, R.W.-M.; Yuen, A.P.-W.; Wei, W.I. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14, 2588–2592. [Google Scholar] [CrossRef] [Green Version]
- Yamamoto, A.; Toba, M.; Takahashi, Y.; Takakura, Y. Pharmacokinetic Approach for the Elucidation of Elevated Plasma Small Extracellular Vesicle (sEV) Concentration in Cancer. J. Pharm. Sci. 2023, 112, 1967–1974. [Google Scholar] [CrossRef] [PubMed]
- Brinton, L.T.; Sloane, H.S.; Kester, M.; Kelly, K.A. Formation and role of exosomes in cancer. Cell. Mol. Life Sci. 2015, 72, 659–671. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, C.; Zheng, S.; Luo, Y.; Wang, B. Exosome theranostics: Biology and translational medicine. Theranostics 2018, 8, 237. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, A.-K.; Giebel, B. Exosomes: Small vesicles participating in intercellular communication. Int. J. Biochem. Cell Biol. 2012, 44, 11–15. [Google Scholar] [CrossRef] [PubMed]
- Al-Qatati, A.; Akrong, C.; Stevic, I.; Pantel, K.; Awe, J.; Saranchuk, J.; Drachenberg, D.; Mai, S.; Schwarzenbach, H. Plasma microRNA signature is associated with risk stratification in prostate cancer patients. Int. J. Cancer 2017, 141, 1231–1239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fredsøe, J.; Rasmussen, A.K.I.; Mouritzen, P.; Bjerre, M.T.; Østergren, P.; Fode, M.; Borre, M.; Sørensen, K.D. Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential. Diagnostics 2020, 10, 188. [Google Scholar] [CrossRef] [Green Version]
- Pollard, J.; Burns, P.A.; Hughes, T.A.; Ho-Yen, C.; Jones, J.L.; Mukherjee, G.; Omoniyi-Esan, G.O.; Titloye, N.A.; Speirs, V.; Shaaban, A.M. Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities. Pathobiology 2018, 85, 220–226. [Google Scholar] [CrossRef]
- Cui, J. MiR-16 family as potential diagnostic biomarkers for cancer: A systematic review and meta-analysis. Int. J. Clin. Exp. Med. 2015, 8, 1703–1714. [Google Scholar]
- Ottman, R.; Ganapathy, K.; Lin, H.-Y.; Osterman, C.D.; Dutil, J.; Matta, J.; Ruiz-Deya, G.; Wang, L.; Yamoah, K.; Berglund, A.; et al. Differential Expression of miRNAs Contributes to Tumor Aggressiveness and Racial Disparity in African American Men with Prostate Cancer. Cancers 2023, 15, 2331. [Google Scholar] [CrossRef]
- Theodore, S.C.; Rhim, J.S.; Turner, T.; Yates, C. MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Ethn. Dis. 2010, 20, S1–S96. [Google Scholar]
- Wang, B.-D.; Ceniccola, K.; Yang, Q.; Andrawis, R.; Patel, V.; Ji, Y.; Rhim, J.; Olender, J.; Popratiloff, A.; Latham, P.; et al. Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities. Clin. Cancer Res. 2015, 21, 4970–4984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ali, H.E.A.; Gaballah, M.S.A.; Gaballa, R.; Mahgoub, S.; Hassan, Z.A.; Toraih, E.A.; Drake, B.F.; Elmageed, Z.Y.A. Small Extracellular Vesicle-Derived microRNAs Stratify Prostate Cancer Patients According to Gleason Score, Race and Associate with Survival of African American and Caucasian Men. Cancers 2021, 13, 5236. [Google Scholar] [CrossRef]
- Yang, Y.; Jia, D.; Kim, H.; Elmageed, Z.Y.A.; Datta, A.; Davis, R.; Srivastav, S.; Moroz, K.; Crawford, B.E.; Moparty, K.; et al. Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer. Clin. Cancer Res. 2016, 22, 1744–1756. [Google Scholar] [CrossRef] [Green Version]
- Shiina, M.; Hashimoto, Y.; Kato, T.; Yamamura, S.; Tanaka, Y.; Majid, S.; Saini, S.; Varahram, S.; Kulkarni, P.; Dasgupta, P.; et al. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget 2016, 8, 8356–8368. [Google Scholar] [CrossRef] [Green Version]
- Shiina, M.; Hashimoto, Y.; Kulkarni, P.; Dasgupta, P.; Shahryari, V.; Yamamura, S.; Tanaka, Y.; Dahiya, R. Role of miR-182/PDCD4 axis in aggressive behavior of prostate cancer in the African Americans. BMC Cancer 2021, 21, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Baumann, B.; Acosta, A.M.; Richards, Z.; Deaton, R.; Sapatynska, A.; Murphy, A.; Kajdacsy-Balla, A.; Gann, P.H.; Nonn, L. Association of High miR-182 Levels with Low-Risk Prostate Cancer. Am. J. Pathol. 2019, 189, 911–923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hashimoto, Y.; Shiina, M.; Dasgupta, P.; Kulkarni, P.; Kato, T.; Wong, R.K.; Tanaka, Y.; Shahryari, V.; Maekawa, S.; Yamamura, S.; et al. Upregulation of miR-130b Contributes to Risk of Poor Prognosis and Racial Disparity in African-American Prostate Cancer. Cancer Prev. Res. 2019, 12, 585–598. [Google Scholar] [CrossRef]
- Hashimoto, Y.; Shiina, M.; Kato, T.; Yamamura, S.; Tanaka, Y.; Majid, S.; Saini, S.; Shahryari, V.; Kulkarni, P.; Dasgupta, P.; et al. The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget 2017, 8, 16581–16593. [Google Scholar] [CrossRef] [Green Version]
- Calin, G.A.; Croce, C.M. MicroRNA Signatures in Human Cancers. Nat. Rev. Cancer 2006, 6, 857–866. [Google Scholar] [CrossRef]
- Ren, Q.; Liang, J.; Wei, J.; Basturk, O.; Wang, J.; Daniels, G.; Gellert, L.L.; Li, Y.; Shen, Y.; Osman, I.; et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am. J. Transl. Res. 2014, 6, 329–339. [Google Scholar]
- Theodore, S.C.; Davis, M.; Zhao, F.; Wang, H.; Chen, D.; Rhim, J.; Dean-Colomb, W.; Turner, T.; Ji, W.; Zeng, G.; et al. MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget 2014, 5, 3512–3525. [Google Scholar] [CrossRef] [Green Version]
- Srivastava, A.; Goldberger, H.; Dimtchev, A.; Ramalinga, M.; Chijioke, J.; Marian, C.; Oermann, E.K.; Uhm, S.; Kim, J.S.; Chen, L.N.; et al. MicroRNA Profiling in Prostate Cancer—The Diagnostic Potential of Urinary miR-205 and miR-214. PLoS ONE 2013, 8, e76994. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Campbell, M.J.; Yates, C.; Long, M.D.; Sucheston-Campbell, L. miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. Front. Biosci. 2017, 22, 212–229. [Google Scholar] [CrossRef] [Green Version]
- Gujrati, H.; Ha, S.; Waseem, M.; Wang, B.-D. Downregulation of miR-99b-5p and Upregulation of Nuclear mTOR Cooperatively Promotes the Tumor Aggressiveness and Drug Resistance in African American Prostate Cancer. Int. J. Mol. Sci. 2022, 23, 9643. [Google Scholar] [CrossRef] [PubMed]
Samples | Age (Year) | PSA (ng/mL) | Ethnicity | Gleason Score | Clinical Stage | NCCN Classification |
---|---|---|---|---|---|---|
SAPC0164 | 74.2 | 2.5 | Black | 3 + 3 | T1a | Very low |
SAPC0203 | 66.8 | 18.6 | Coloured | 3 + 3 | cT2a | Intermediate |
SAPC0238 | 92.5 | 24.4 | Coloured | 3 + 3 | T1a | High |
SAPC0185 | 69.0 | 18.0 | Coloured | 4 + 5 | T2c | High |
SAPC0195 | 87.2 | 26.5 | Black | 4 + 5 | T3 | Very high |
SAPC0180 | 58.1 | >5000 | Black | 5 + 5 | T3/T4 | Very high |
EV miRNA | TCGA PCa Tissue miRNA | |||||
---|---|---|---|---|---|---|
LogFC | p-Value | FDR | LogFC | p-Value | FDR | |
hsa-miR-10a-5p | 9.21 | 2.78 × 10−4 | 2.92 × 10−3 | 0.30 | 9.52 × 10−5 | 1.11 × 10−3 |
hsa-miR-194-5p | 3.45 | 5.11 × 10−3 | 3.34 × 10−2 | 0.25 | 3.41 × 10−6 | 5.95 × 10−5 |
hsa-miR-144-5p | 2.30 | 5.72 × 10−3 | 3.56 × 10−2 | 0.27 | 7.70 × 10−3 | 4.91 × 10−2 |
hsa-miR-16-5p | 1.89 | 1.67 × 10−2 | 8.05 × 10−2 | 0.19 | 4.42 × 10−6 | 7.34 × 10−5 |
hsa-miR-221-5p | −2.08 | 1.83 × 10−2 | 8.51 × 10−2 | −0.55 | 1.55 × 10−12 | 6.77 × 10−11 |
hsa-miR-326 | −2.15 | 1.84 × 10−2 | 8.51 × 10−2 | −0.33 | 5.26 × 10−4 | 4.83 × 10−3 |
hsa-miR-93-5p | 1.67 | 1.85 × 10−2 | 8.51 × 10−2 | 0.35 | 9.74 × 10−9 | 2.55 × 10−7 |
Feature | BPH (n = 10) | Low GS (n = 12) | High GS (n = 7) | Metastatic (n = 5) | p-Value |
---|---|---|---|---|---|
Age (year), median [IQR] | 68 (66–74) | 67 (62–71) | 81 (76–84) | 63 (62–75) | 3.66 × 10−2 |
PSA (ng/mL), median [IQR] | 5.3 (3.9–11.3) | 11.1 (6.5–18.7) | 39.3 (22.5–109) | 1070 (576–5000) | 2.25 × 10−4 |
Ethnicity | 1.50 × 10−1 | ||||
Black, n (%) | 6 (60.0) | 1 (8.3) | 3 (42.9) | 2 (40.0) | |
Coloured, n (%) | 4 (40.0) | 9 (75.0) | 3 (42.9) | 2 (40.0) | |
White, n (%) | 0 (0.0) | 2 (16.7) | 1 (14.3) | 1 (20.0) | |
CRP (ng/mL), median [IQR] | - | 5.9 (4.2–8.4) | 5.8 (4.3–7.9) | 291 (62–405) | 1.89 × 10−2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Temilola, D.O.; Wium, M.; Paccez, J.; Salukazana, A.S.; Otu, H.H.; Carbone, G.M.; Kaestner, L.; Cacciatore, S.; Zerbini, L.F. Potential of miRNAs in Plasma Extracellular Vesicle for the Stratification of Prostate Cancer in a South African Population. Cancers 2023, 15, 3968. https://doi.org/10.3390/cancers15153968
Temilola DO, Wium M, Paccez J, Salukazana AS, Otu HH, Carbone GM, Kaestner L, Cacciatore S, Zerbini LF. Potential of miRNAs in Plasma Extracellular Vesicle for the Stratification of Prostate Cancer in a South African Population. Cancers. 2023; 15(15):3968. https://doi.org/10.3390/cancers15153968
Chicago/Turabian StyleTemilola, Dada Oluwaseyi, Martha Wium, Juliano Paccez, Azola Samkele Salukazana, Hasan H. Otu, Giuseppina M. Carbone, Lisa Kaestner, Stefano Cacciatore, and Luiz Fernando Zerbini. 2023. "Potential of miRNAs in Plasma Extracellular Vesicle for the Stratification of Prostate Cancer in a South African Population" Cancers 15, no. 15: 3968. https://doi.org/10.3390/cancers15153968